Aug 14 (Reuters) - The U.S. Food and Drug Administration
said on Wednesday it has approved Gilead Sciences' ( GILD ) drug
for a chronic and potentially fatal liver disease that mostly
affects women.
The disease, primary biliary cholangitis (PBC), causes
inflammation of the small bile ducts in the liver and can
eventually destroy them. It mainly affects women aged 35 to 60.